Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7)

Health-related quality of life in premenopausal women with hormone-receptor-positive, HER2-negative advanced breast cancer treated with ribociclib plus endocrine therapy: results from a phase III randomized clinical trial (MONALEESA-7) PER SAPERNE DI PIÙ »

Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies

Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies PER SAPERNE DI PIÙ »

Questo sito web è destinato esclusivamente all’uso da parte di professionisti del settore sanitario. Continuando a consultare questo sito, confermate di essere operatori sanitari.

 

This site is only for use by healthcare professionals. By continuing to view this site you are confirming that you are a healthcare professional.

Conferma